Viridian Therapeutics
VRDN
VRDN
122 hedge funds and large institutions have $1.21B invested in Viridian Therapeutics in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 52 increasing their positions, 29 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
2.77% more ownership
Funds ownership: 99.68% → 102.45% (+2.8%)
3% less call options, than puts
Call options by funds: $3.47M | Put options by funds: $3.58M
Holders
122
Holding in Top 10
11
Calls
$3.47M
Puts
$3.58M
Top Buyers
| 1 | +$27M | |
| 2 | +$24.1M | |
| 3 | +$22.8M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$20M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$17.2M |
Top Sellers
| 1 | -$19.8M | |
| 2 | -$16.2M | |
| 3 | -$14.7M | |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$10.8M |
| 5 |
EP
Eversept Partners
New York
|
-$9.81M |